Validation Requirements for Disinfection Efficacy - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Validation Requirements for Disinfection Efficacy


Pharmaceutical Technology
Volume 37, Issue 1, pp. 35

RELATED ARTICLES

More in GMPs/Validation

Q Is the periodic re-evaluation of disinfectant efficacy useful in any way? I have been asked to repeat these studies even though they have been done in the past. There's been no change to the materials or methods since that time.


John S. Kent
A In the pharmaceutical manufacturing industry, operating under GMPs, the periodic revalidation of disinfection efficacy is not scientifically justified or required provided the disinfectant used remains the same, the dilution of the disinfectant is still the same, the challenge organisms (including environmental isolates) are still the same, the manufacturing environment surfaces are still the same and the vendor for the disinfectant is still the same. To my knowledge, only when one of these five elements regarding cleanroom disinfection is changed are you required to repeat the validation of disinfection efficacy testing. Periodic revalidation of a disinfectant serves no useful scientific purpose and I do not know of an FDA regulation that states that one must periodically revalidate disinfectants. Be sure to execute the disinfection efficacy validation properly and have complete documentation.

John S. Kent, PhD
Principal, Pharmaceutical Development Consulting
San Mateo, CA (USA) 94403

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
25%
Oversee medical treatment of patients in the US.
13%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here